Boston Scientific/Penumbra: Divestiture Buyer Sought for Embolization Coils Business to Address FTC Concerns

Boston Scientific (BSX) is seeking a divestiture buyer for an embolization coil business to get FTC clearance for its proposed $14.5 billion acquisition of Penumbra (PEN), sources familiar with the matter said

Published on Oct 19, 2026

Already have an account? Log in.

This article is currently locked and only available to subscribers. Request a trial to receive unlimited access to all articles.

View Only Unlocked Articles

Copyright ©2026 The Capitol Forum. All Rights Reserved.